Aminowel

# Aminowel ## Overview - **Classification**: Parenteral Amino Acid Solution, component of Total Parenteral Nutrition (TPN) - **Mechanism**: Provides crystalline essential and non-essential amino acids necessary for protein synthesis, tissue repair, and nitrogen balance in patients unable to meet nutritional needs enterally. ## Primary Indications 1. **Nutritional Support**: For patients requiring intravenous nutritional support due to inability to tolerate or absorb enteral nutrition. 2. **Protein Supplementation**: To maintain or restore positive nitrogen balance in hypercatabolic states (e.g., trauma, burns, sepsis). 3. **Specific Conditions**: Conditions such as short bowel syndrome, severe pancreatitis, inflammatory bowel disease, or prolonged NPO status. ## Adult Dosing ### Standard Dosing **Parenteral Nutrition Support** - **Dose**: Typically **0.8 to 1.5 g amino acids/kg/day** - **Frequency**: Continuous infusion over 24 hours (as part of TPN) - **Route**: Intravenous (peripheral or central line, depending on osmolality) - **Maximum**: Up to **2.5 g amino acids/kg/day** in highly catabolic states; usually **20-25% of total caloric intake**. - **Considerations**: Aminowel is often supplied as 5%, 10%, or 15% solutions; volume administered depends on desired protein intake. ### Dose Adjustments - **Renal Impairment**: Reduce amino acid intake to **0.6-0.8 g/kg/day** in severe renal failure. Monitor BUN, creatinine, and electrolytes closely. May require specialized renal amino acid formulations. - **Hepatic Impairment**: Reduce amino acid intake to **0.5-0.7 g/kg/day** in severe hepatic encephalopathy. Monitor ammonia levels and mental status. May require specialized hepatic amino acid formulations. - **Elderly Patients**: Start at lower end of dosing range. Closely monitor fluid balance, renal function, and metabolic status due to age-related physiological changes. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Start **1.5 to 2.5 g amino acids/kg/day**. Advance as tolerated. - **Frequency**: Continuous infusion over 24 hours. - **Maximum**: Up to **3.5 g amino acids/kg/day**. - **Special Notes**: Highly individualized. Monitor serum amino acid levels if available. Higher needs for premature infants. ### Infants (1-12 months) - **Dose**: Start **1.5 to 2.5 g amino acids/kg/day**. - **Frequency**: Continuous infusion over 24 hours. - **Maximum**: Up to **3.0 g amino acids/kg/day**. ### Children (1-12 years) - **Dose**: **0.8 to 1.5 g amino acids/kg/day**. - **Frequency**: Continuous infusion over 24 hours. - **Maximum**: **2.0-2.5 g amino acids/kg/day** depending on clinical status. ### Adolescents (13-18 years) - **Dose**: Approaches adult dosing, typically **0.8 to 1.5 g amino acids/kg/day**. - **Maximum**: Up to **2.5 g amino acids/kg/day**. ## Safety Information ### Contraindications - **Absolute**: Severe uncompensated hepatic failure leading to coma. - **Absolute**: Severe uremia or anuria without access to dialysis. - **Absolute**: Hypersensitivity to any component of the solution (e.g., amino acids, bisulfites if present). - **Absolute**: Severe fluid overload or uncontrolled electrolyte imbalances. - **Relative**: Inborn errors of amino acid metabolism (use with extreme caution). ### Common Adverse Effects - **Common (1-10%)**: Nausea, vomiting, fever, flushing. - **Common (1-10%)**: Electrolyte imbalances (e.g., hypokalemia, hypophosphatemia). - **Common (1-10%)**: Metabolic acidosis (due to chloride content). - **Serious but Rare**: Refeeding syndrome, hyperammonemia, hepatic dysfunction (cholestasis, steatosis), catheter-related bloodstream infection (CRBSI), anaphylaxis. ### Key Drug Interactions - **None specific**: Amino acid solutions typically do not have direct drug interactions in the same way as pharmacologically active drugs. - **Metabolic interactions**: Requires careful consideration with other TPN components (dextrose, lipids, electrolytes, vitamins, trace elements) to ensure metabolic compatibility and patient tolerance. - **Diuretics**: May alter fluid and electrolyte balance; monitor closely. ## Monitoring & Follow-up - **Before Treatment**: Baseline weight, complete blood count (CBC), liver function tests (LFTs), renal function panel (BUN, creatinine), electrolytes (Na, K, Cl, CO2, Mg, P, Ca), glucose. - **During Treatment**: * **Daily initially**: Electrolytes, glucose, BUN, creatinine. * **Weekly or bi-weekly**: LFTs, CBC, magnesium, phosphorus, calcium, triglycerides. * **Periodically**: Prealbumin, albumin, transferrin (for nutritional status). - **Clinical Signs**: Monitor fluid balance (I&O), weight changes, signs of infection (fever, chills, catheter site), signs of refeeding syndrome (fluid retention, arrhythmias, weakness). ## Clinical Pearls - 💡 **Individualized therapy**: Amino acid dosing is highly individualized based on patient's protein requirements, metabolic state, and renal/hepatic function. - 💡 **Central vs. Peripheral**: Solutions > **900 mOsm/L** (e.g., >10% dextrose, >5% amino acids) require central venous access to prevent vein irritation and phlebitis. - 💡 **Compatibility**: Always verify compatibility with other TPN components and admixed medications to prevent precipitation or instability. - 💡 **Refeeding Syndrome**: Introduce TPN slowly, especially in severely malnourished patients, to avoid refeeding syndrome. Closely monitor electrolytes (P, K, Mg) and glucose. - 💡 **Aseptic Technique**: Strict aseptic technique is critical for TPN preparation and administration to prevent catheter-related bloodstream infections. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.